Replacement therapy with coagulation factor VIII (FVIII) represents the current clinical treatment for patients affected by hemophilia A (HA). This treatment while effective is. however. hampered by the formation of antibodies which inhibit the activity of infused FVIII in up to 30% of treated patients. https://countryscenesaddleryandpetsuppliers.shop/product-category/saddle-accessories/